Country:
Years:
Category:

Red Arrow Therapeutics Inc.

Red Arrow Therapeutics’ chemists shape the behavior of proteins by carefully designing polymer-protein conjugates with controlled architecture, composition, size and stimuli responsive chemistry. Our unique approach can then generate prodrug-like proteins with optimal pharmacokinetics, biodistribution and targeted activation at disease sites without compromising the biological action of the proteins. With our novel platform, a broad range of valuable functional attributes will become accessible for therapeutic innovation. As a 1st pipeline, we focused on immunotherapy, where only 20% patients respond to standard immunoncological options, such as immune checkpoint inhibitors (ICIs). Because the immunosuppressive environment of cold tumors is the major reason for immunotherapy failure, Red Arrow Therapeutics has developed protein prodrugs that safely boost antitumor immunity. To this end, we have identified the hit formulation capable of tumor eradication, even in malignancies that are resistant to ICIs, and we will optimize this formulation before large-scale manufacturing, pre-clinical trials and clinical trials. We are convinced that our proprietary platform will attract Japanese investors and pharmaceuticals to jointly develop products, and we aim to achieve IPO with our pipelines toward blockbuster drugs and alliances.

Read More→

MOTORICA LLC

Motorica is a company with offices in Russia (HQ), China and India focusing on research and development in medicine and robotics. Since its establishment, the company has been developing artificial hand systems and rehabilitation with assistive technologies. Half of the team are R&D staff and medical specialists.
 Motorica challenges the outdated ideas about prosthetic care. The team taught prostheses to communicate with the user, go online, perform voice commands, pay for purchases. In 2018, Motorica launched the development of a rehabilitation platform based on virtual reality and a platform for collecting telemetry via gsm-module in prosthetic devices. Nowadays, people with disabilities become the primary users of the cyber technology market and turn weaknesses into strengths.

Read More→

Acumen Research Labs

Acumen has developed AcuSeptTM — a novel, blood-based Sepsis Host Response test using sepsis-specific mRNA biomarkers — that can assist the doctos to detect sepsis in patients in 4-5 hrs, earlier and more accurately than current methods.

Intended Use:
AcuSeptTM generates diagnostic scores which fall in the range of either above or below a validated threshold level that determines the risk of sepsis. AcuSeptTM results are to be used in conjunction with clinical assessments and other laboratory findings as an aid to identify patients with low or high risk of infection and sepsis.

Clinical Utility:
・To differentiate patients with and without infection
・To differentiate patients with and without sepsis
・Can identify sepsis early

Read More→

Advent Access Pte Ltd

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ – an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably – at home or in novel care environments.
For more information on Advent Access, please visit http://www.adventaccess.com/

Read More→

Craft Health Pte Ltd

At Craft Health, we are building a platform for 3D printed personalized healthcare. Possible applications include personalized nutrition, decentralized clinical trials, personalized medicine, and 3D printing for orphan drugs.

Since we launched in May 2019, we have:

Hardware: In-house developed 3D printer specialized for nutraceuticals and pharmaceuticals. Our 3D printer is designed for Good Manufacturing Practice (GMP) and the 3D printing process does not involve heat or ultraviolet (UV) curing, enabling a wide range of active ingredients to be used.
Software: 3D printing software
3D printable formulations: A series of proprietary 3D printable formulations for different controlled released profiles (Immediate/sustained/delayed release) that can be combined in a single 3D printed tablet.
Specialty products: Patent pending 3D printed capsule that converts once daily dosing to once weekly.

Read More→

BioCheetah Pte Ltd

BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is in the midst of building an ISO 13485 production facility at Block 79, JTC LaunchPad in Singapore, setting up its Quality Management System (QMS) for the purpose of development and manufacturing of its diagnostic products as well as in discussion with SingHealth and overseas hospitals for clinical validation of the to-be-developed bladder cancer diagnostic products.

Read More→

DotSpace Biomedical Inc.

DotSpace biomedical Inc. devoting their talents to provide of Medical Internet of Thing (MIoT) solutions, integrating hardware, software and database systems, and expanding from clinical intensive care to other clinical monitoring and health examinations. DotSpace biomedical Inc. is a preclinical-stage company taking a targeted approach in the development of realtime wireless intra-abdominal hypertension monitoring system to improve critical intensive care. We are delveloping a capsulized pressure sensor effectively transmit data in monitoring key intra-abdominal pressure and motility believed to be involved in acute pancreatitis, trauma, infection and inflammatory bowel disorders.

Two distinct, first-in-class devices have been developed that precisely detect gastrointestinal physiological changes—with minimal invasive process that has little side effects seen with other methods from this class. DotSpace biomedical Inc. is positioned to deliver a intra-abdominal monitoring system for FDA approval approximately 12 months after program funding, and their intention is to pursue integration in standard intensive care monitoring system.

Read More→

KURA Care Inc

Promotional description of the business: heart disease is the number 1 reason for death in the US. The medical cost for heart failure will be $69B by 2030, and an estimated 26 million people suffer. As the entire world steps into an aging society, this problem will worsen and eventually make our healthcare system not sustainable. Our solution can effectively reduce the mortality rate and save medical costs by empowering patients to manage their health more effectively and help physicians take care of patients more efficiently.

Motivation for starting the business: I am a Leukemia survivor, and I spent lots of time in the hospital to fight my cancer. During a hospital stay at the University of California, San Diego (UCSD), I carefully observed clinical workflow and found many opportunities. Meanwhile, I have over 15 years of experience researching and commercializing Artificial Intelligence (AI) products; Qualcomm sponsored my Ph.D. Therefore, I decided to use AI to craft future healthcare and wish people like me could suffer less, eventually, fewer people like me.

Read More→